Inflation, then deflation

Despite statistical error, NeuroSearch says Huntington's program is on track

Three months ago, NeuroSearch A/S became one of the hottest stocks in European biotech when its share price almost doubled in response to top-line data from the Phase III MermaiHD trial of Huntexil pridopidine in Huntington's disease. All things considered, the company got off better than it might have last week after revealing three pieces of bad news: an error in analysis that changed the result of MermaiHD, delays in its other Phase III program, and the likelihood that GlaxoSmithKline plc will

Read the full 827 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE